References
1. Centers for Disease Control and Prevention
(CDC) (1999) Impact of vaccines universally
recommended for children--United States,
1990-1998. MMWR Morb Mortal Wkly Rep
48(12):243
2. Whitney CG, Zhou F, Singleton J, Schuchat A
(2014) Benefits from immunization during the
vaccines for children program era-United
States, 1994-2013. MMWR Morb Mortal
Wkly Rep 63(16):352–355
3. Szucs T (2000) Cost-benefits of vaccination
programmes. Vaccine 18(Suppl 1):S49–S51.
https://doi.org/10.1016/S0264-410X(99)
00464-8
4. Scorpio A, Blank TE, Day WA, Chabot DJ
(2006) Anthrax vaccines: pasteur to the present. Cell Mol 63(19-20):2237–2248. https://
doi.org/10.1007/s00018-006-6312-3
5. Smith KA (2012) Louis Pasteur, the father of
immunology? Front Immunol 3:68. https://
doi.org/10.3389/fimmu.2012.00068
6. Turner GS, Squires EJ, Murray HGS (1970)
Inactivated smallpox vaccine. A comparison of
inactivation methods. J Hyg 68(2):197–210.
https://doi.org/10.1017/
s0022172400028679
7. Moyle PM, Toth I (2013) Modern subunit
vaccines: development, components, and
research opportunities. ChemMedChem 8
(3):360–376.
https://doi.org/10.1002/
cmdc.201200487
8. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A,
Vosters O, Vanderheyde N, Schiavetti F,
Larocque D, Van Mechelen M, Garcon N
(2009) AS04, an aluminum salt- and TLR4
agonist-based adjuvant system, induces a transient localized innate immune response leading
to enhanced adaptive immunity. J Immunol
183(10):6186–6197.
https://doi.org/10.
4049/jimmunol.0901474
9. Heijmans S, De Meulemeester M, Reynders P,
Giet D, Demanet E, Devresse P-Y, Icardi G,
Drame ´ M, Roman F, Gillard P (2011) Immunogenicity profile of a 3.75-μg hemagglutinin
pandemic rH5N1 split virion AS03(A)adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 203(8):1054–1062.
https://doi.org/10.1093/infdis/jiq174
10. Weintraub A (2003) Immunology of bacterial
polysaccharide antigens. Carbohydr Res 338
(23):2539–2547. https://doi.org/10.1016/j.
carres.2003.07.008
11. CDC (2000) Active bacterial core surveillance
report, emerging infections program network,
Streptococcus pneumoniae, 1999. Centers for
Disease Control and Prevention, Paris
12. CDC (2015) Active bacterial core surveillance
report, emerging infections program network,
Streptococcus pneumoniae, 2015. Centers for
Disease Control and Prevention, Paris
13. Hill AB, Beitelshees M, Nayerhoda R, Pfeifer
BA, Jones CH (2018) Engineering a nextgeneration glycoconjugate-like streptococcus
pneumoniae vaccine. ACS Infect Dis 4:1553.
https://doi.org/10.1021/acsinfecdis.
8b00100
14. Jones CH, Zhang G, Nayerhoda R,
Beitelshees M, Hill A, Rostami P, Li Y, Davidson BA, Knight P, Pfeifer BA (2017) Comprehensive vaccine design for commensal disease
progression. Sci Adv 3(10):e1701797. https://
doi.org/10.1126/sciadv.1701797
15. Andrews NJ, Waight PA, Burbidge P, Pearce E,
Roalfe L, Zancolli M, Slack M, Ladhani SN,
Miller E, Goldblatt D (2014) Serotype-specific
effectiveness and correlates of protection for
the 13-valent pneumococcal conjugate vaccine:
a postlicensure indirect cohort study. Lancet
Infect Dis 14(9):839–846. https://doi.org/
10.1016/S1473-3099(14)70822-9
16. Roush SW, Murphy TV (2007) Historical comparisons of morbidity and mortality for
vaccine-preventable diseases in the United
States. JAMA 298(18):2155–2163. https://
doi.org/10.1001/jama.298.18.2155
8
Andrew Hill et al.
1. Centers for Disease Control and Prevention
(CDC) (1999) Impact of vaccines universally
recommended for children--United States,
1990-1998. MMWR Morb Mortal Wkly Rep
48(12):243
2. Whitney CG, Zhou F, Singleton J, Schuchat A
(2014) Benefits from immunization during the
vaccines for children program era-United
States, 1994-2013. MMWR Morb Mortal
Wkly Rep 63(16):352–355
3. Szucs T (2000) Cost-benefits of vaccination
programmes. Vaccine 18(Suppl 1):S49–S51.
https://doi.org/10.1016/S0264-410X(99)
00464-8
4. Scorpio A, Blank TE, Day WA, Chabot DJ
(2006) Anthrax vaccines: pasteur to the present. Cell Mol 63(19-20):2237–2248. https://
doi.org/10.1007/s00018-006-6312-3
5. Smith KA (2012) Louis Pasteur, the father of
immunology? Front Immunol 3:68. https://
doi.org/10.3389/fimmu.2012.00068
6. Turner GS, Squires EJ, Murray HGS (1970)
Inactivated smallpox vaccine. A comparison of
inactivation methods. J Hyg 68(2):197–210.
https://doi.org/10.1017/
s0022172400028679
7. Moyle PM, Toth I (2013) Modern subunit
vaccines: development, components, and
research opportunities. ChemMedChem 8
(3):360–376.
https://doi.org/10.1002/
cmdc.201200487
8. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A,
Vosters O, Vanderheyde N, Schiavetti F,
Larocque D, Van Mechelen M, Garcon N
(2009) AS04, an aluminum salt- and TLR4
agonist-based adjuvant system, induces a transient localized innate immune response leading
to enhanced adaptive immunity. J Immunol
183(10):6186–6197.
https://doi.org/10.
4049/jimmunol.0901474
9. Heijmans S, De Meulemeester M, Reynders P,
Giet D, Demanet E, Devresse P-Y, Icardi G,
Drame ´ M, Roman F, Gillard P (2011) Immunogenicity profile of a 3.75-μg hemagglutinin
pandemic rH5N1 split virion AS03(A)adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 203(8):1054–1062.
https://doi.org/10.1093/infdis/jiq174
10. Weintraub A (2003) Immunology of bacterial
polysaccharide antigens. Carbohydr Res 338
(23):2539–2547. https://doi.org/10.1016/j.
carres.2003.07.008
11. CDC (2000) Active bacterial core surveillance
report, emerging infections program network,
Streptococcus pneumoniae, 1999. Centers for
Disease Control and Prevention, Paris
12. CDC (2015) Active bacterial core surveillance
report, emerging infections program network,
Streptococcus pneumoniae, 2015. Centers for
Disease Control and Prevention, Paris
13. Hill AB, Beitelshees M, Nayerhoda R, Pfeifer
BA, Jones CH (2018) Engineering a nextgeneration glycoconjugate-like streptococcus
pneumoniae vaccine. ACS Infect Dis 4:1553.
https://doi.org/10.1021/acsinfecdis.
8b00100
14. Jones CH, Zhang G, Nayerhoda R,
Beitelshees M, Hill A, Rostami P, Li Y, Davidson BA, Knight P, Pfeifer BA (2017) Comprehensive vaccine design for commensal disease
progression. Sci Adv 3(10):e1701797. https://
doi.org/10.1126/sciadv.1701797
15. Andrews NJ, Waight PA, Burbidge P, Pearce E,
Roalfe L, Zancolli M, Slack M, Ladhani SN,
Miller E, Goldblatt D (2014) Serotype-specific
effectiveness and correlates of protection for
the 13-valent pneumococcal conjugate vaccine:
a postlicensure indirect cohort study. Lancet
Infect Dis 14(9):839–846. https://doi.org/
10.1016/S1473-3099(14)70822-9
16. Roush SW, Murphy TV (2007) Historical comparisons of morbidity and mortality for
vaccine-preventable diseases in the United
States. JAMA 298(18):2155–2163. https://
doi.org/10.1001/jama.298.18.2155
8
Andrew Hill et al.